Track topics on Twitter Track topics that are important to you
Recent debates about drug pricing have tended to focus on manufacturers and patients, but US Representative Doug Collins is looking at the middlemen.
's stock had its "buy" rating reaffirmed by Canaccord Genuity in a research note issued on Wednesday. They presently have a GBX 325 price target on the stock.
's stock had its "buy" rating reaffirmed by analysts at Beaufort Securities in a research note issued on Thursday, StockTargetPrices.com reports. They currently have a GBX 1,750 target price on the stock.
MONTGOMERY, Texas, Feb. 19, 2017 /PRNewswire/ -- AC Group Inc., a leading company, specializing in the evaluation, selection, and ranking of vendors in the PMS/EHR healthcare marketplace, will exhibit the 7 Stages of VBR technologies and implementational system requirements to succeed in this ecosystem at HIMSS'17. AC Group gathered together information obtained from over 200 ...
Protalix's share price has shot up 300% after plunging following a debt settlement in December.
's stock had its "outperform" rating reissued by research analysts at Sanford C. Bernstein in a research note issued on Thursday. They presently have a $410.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $420.00.
's stock had its "neutral" rating restated by analysts at Cantor Fitzgerald in a report released on Thursday. They presently have a $51.00 target price on the stock.
The Global SelfMonitoring of Blood Glucose Market to 2025' is GMR Data's latest pharma report, covering the pharmaceutical, commercial and strategic developments in the global SelfMonitoring of Blood Glucose SMBG market. The report highlights key companies, geographies and products that we believe will deliver strong growth across the next decade. SMBG is now globally recognised as an integral par...
Kaleo Pharma's Evzio naloxone injector has climbed 600% in price over the last few years, lawmakers say. The company says that's not really a problem.
Medicare beneficiaries with heart failure who were implanted with left ventricular assist devices (LVADs) had a significantly increase in lifetime costs compared with those treated with medical management, according to a cost-effectiveness model.
Join Steve Terman — Principal Attorney, Olson Frank Weeda Terman Matz — and Gordon Schatz — President, Schatz Reimbursement Strategies — on Feb. 22 when they’ll explain how to strategically blend reimbursement with FDA regulatory issues and identify the need for outcomes data, comparative evidence, professional society guidelines and how to meet Medicare and managed care reimbursement st...
Click to view a price quote on AET. Click to research the Health Services industry.
Look for International Scholarship and Tuition Services, Inc. on the HIMSS17 exhibit floor in Orlando Nashville, TN (PRWEB) February 17, 2017 For the first time, International Scholarship and Tuition Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for the 2017 HIMSS Conference & Exhibition at the Orange County Convention Center in Orlando, Fla....
TUCSON, Ariz., Feb. 17, 2017 /PRNewswire/ -- Every sector of the healthcare industry is struggling to figure out what TrumpCare will mean to their businesses. Some will do better under TrumpCare, but most will do worse. There is one sector, however, which is guaranteed to grow like gangbusters under a Trump administration: Healthcare IT. Here's why: First, there will be a sharp uptick in...
Cardinal Health, Inc. Chairman George S. Barrett sold 217,994 shares of the company's stock in a transaction that occurred on Friday, February 10th. The stock was sold at an average price of $77.23, for a total transaction of $16,835,676.62.
Click to view a price quote on CLVS. Click to research the Drugs industry.
Click to view a price quote on TSRO. Click to research the Drugs industry.
Several other research firms have also commented on TEVA. Mizuho lowered shares of Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating and lowered their price objective for the company from $64.00 to $45.00 in a research report on Monday, October 24th.
Click to view a price quote on UNH. Click to research the Health Services industry.
Click to view a price quote on SAGE.
Danish pharmaceutical company Novo Nordisk has pledged to limit the price rises of its drugs to single digit increases each year, following the commitment made by Allergan in September 2016.
PUNE, India, February 17, 2017 /PRNewswire/ -- According to a new market research report "Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021" published by MarketsandMarkets, the market is proj...
Click to view a price quote on CELG. Click to research the Drugs industry.
Click to view a price quote on AZN. Click to research the Drugs industry.
Click to view a price quote on XBI. Click to research the Financial Services industry.